Yirong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yirong Liu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Di Chen
Center for Regeneration and Cell Therapy of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University Center for Reproductive Medicine of The Second Affiliated Hospital Haining 314400
1 shared publication - Huanyu Zhang
Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China
1 shared publication Jiayi Wang
Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
1 shared publicationJin Zhang
Center for Reproductive Medicine of The Second Affiliated Hospital, Center for Regeneration and Cell Therapy of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
1 shared publication- Jing Xie
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
1 shared publication - Juan Wang
School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, 300072, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (5) , 101199
The regulatory role of m6A modification in the maintenance and differentiation of embryonic stem cells
As the most prevalent and reversible internal epigenetic modification in eukaryotic mRNAs, N6-methyladenosine (m6A) post-transcriptionally regulates the processing and metabolism of mRNAs involved in diverse biological processes. m6A modification is regulated by m6A writers, erasers, and readers. Emerging evidence suggests that m6A modification plays essential roles in modulating the cell-fate transition of embryonic stem cells. Mechanistic investigation of embryonic stem cell maintenance and differentiation is critical for understanding early embryonic development, which is also the premise for the application of embryonic stem cells in regenerative medicine. This review highlights the current knowledge of m6A modification and its essential regulatory contribution to the cell fate transition of mouse and human embryonic stem cells.
- 1 September 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (5) , 101199
Open AccessThe regulatory role of m6A modification in the maintenance and differentiation of embryonic stem cells
As the most prevalent and reversible internal epigenetic modification in eukaryotic mRNAs, N6-methyladenosine (m6A) post-transcriptionally regulates the processing and metabolism of mRNAs involved in diverse biological processes. m6A modification is regulated by m6A writers, erasers, and readers. Emerging evidence suggests that m6A modification plays essential roles in modulating the cell-fate transition of embryonic stem cells. Mechanistic investigation of embryonic stem cell maintenance and differentiation is critical for understanding early embryonic development, which is also the premise for the application of embryonic stem cells in regenerative medicine. This review highlights the current knowledge of m6A modification and its essential regulatory contribution to the cell fate transition of mouse and human embryonic stem cells.
- 21 July 2022
- Published by Wiley in Journal of Integrative Plant Biology
- Vol. 64 (9) , 1739-1754
Engineering of triterpene metabolism and overexpression of the lignin biosynthesis gene PAL promotes ginsenoside Rg3 accumulation in ginseng plant chassis
The ginsenoside Rg3 found in Panax species has extensive pharmacological properties, in particular anti‐cancer effects. However, its natural yield in Panax plants is limited. Here, we report a multi‐modular strategy to improve yields of Rg3 in a Panax ginseng chassis, combining engineering of triterpene metabolism and overexpression of a lignin biosynthesis gene, phenylalanine ammonia lyase (PAL). We first performed semi‐rational design and site mutagenesis to improve the enzymatic efficiency of Pq3‐O‐UGT2, a glycosyltransferase that directly catalyzes the biosynthesis of Rg3 from Rh2. Next, we used clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) gene editing to knock down the branch pathway of protopanaxatriol‐type ginsenoside biosynthesis to enhance the metabolic flux of the protopanaxadiol‐type ginsenoside Rg3. Overexpression of PAL accelerated the formation of the xylem structure, significantly improving ginsenoside Rg3 accumulation (to 6.19‐fold higher than in the control). We combined overexpression of the ginsenoside aglycon synthetic genes squalene epoxidase, Pq3‐O‐UGT2, and PAL with CRISPR/Cas9‐based knockdown of CYP716A53v2 to improve ginsenoside Rg3 accumulation. Finally, we produced ginsenoside Rg3 at a yield of 83.6 mg/L in a shake flask (7.0 mg/g dry weight, 21.12‐fold higher than with wild‐type cultures). The high‐production system established in this study could be a potential platform to produce the ginsenoside Rg3 commercially for pharmaceutical use.
- 21 July 2022
- Published by Wiley in Journal of Integrative Plant Biology
- Vol. 64 (9) , 1739-1754
Engineering of triterpene metabolism and overexpression of the lignin biosynthesis gene PAL promotes ginsenoside Rg3 accumulation in ginseng plant chassis
The ginsenoside Rg3 found in Panax species has extensive pharmacological properties, in particular anti‐cancer effects. However, its natural yield in Panax plants is limited. Here, we report a multi‐modular strategy to improve yields of Rg3 in a Panax ginseng chassis, combining engineering of triterpene metabolism and overexpression of a lignin biosynthesis gene, phenylalanine ammonia lyase (PAL). We first performed semi‐rational design and site mutagenesis to improve the enzymatic efficiency of Pq3‐O‐UGT2, a glycosyltransferase that directly catalyzes the biosynthesis of Rg3 from Rh2. Next, we used clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) gene editing to knock down the branch pathway of protopanaxatriol‐type ginsenoside biosynthesis to enhance the metabolic flux of the protopanaxadiol‐type ginsenoside Rg3. Overexpression of PAL accelerated the formation of the xylem structure, significantly improving ginsenoside Rg3 accumulation (to 6.19‐fold higher than in the control). We combined overexpression of the ginsenoside aglycon synthetic genes squalene epoxidase, Pq3‐O‐UGT2, and PAL with CRISPR/Cas9‐based knockdown of CYP716A53v2 to improve ginsenoside Rg3 accumulation. Finally, we produced ginsenoside Rg3 at a yield of 83.6 mg/L in a shake flask (7.0 mg/g dry weight, 21.12‐fold higher than with wild‐type cultures). The high‐production system established in this study could be a potential platform to produce the ginsenoside Rg3 commercially for pharmaceutical use.